Axon Enterprise develops technology solutions for law enforcement and public safety agencies. Its core products include body-worn cameras, digital evidence management software, and tasers. The company operates primarily in the public safety sector, with major revenue sources stemming from hardware sales, software subscriptions, and service contracts. Axon aims to enhance transparency and accountability in policing through its innovative solutions.
The investment profile of Axon Enterprise is more aligned with growth investors, given its focus on innovation and technology in the public safety sector. The company does not currently offer dividends, which may not appeal to income-focused investors. Its performance suggests a higher risk profile, suitable for those with a medium to long-term investment horizon.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-10-13 | Hold | Sell | Weak momentum and high risk overshadow potential growth. |
| 2026-10-01 | Sell | Hold | Weak momentum and high risk; cautious approach advised. |
| 2026-09-18 | Hold | Sell | Weak momentum and high risk overshadow potential growth. |
| 2026-08-29 | Buy | Hold | Strong growth but recent momentum weakness raises concerns. |
| 2026-08-02 | Hold | Buy | Strong momentum but recent volatility raises concerns. |
| 2026-07-31 | Buy | Hold | Mixed performance; high risk with uncertain momentum. |
| 2026-07-29 | Hold | Buy | Strong recent performance and positive EPS surprise. |
| 2026-07-23 | Buy | Hold | Weak momentum and high risk; cautious approach advised. |
| 2026-07-21 | Hold | Buy | Strong momentum and positive earnings surprise support growth outlook. |
| 2026-07-11 | Buy | Hold | Mixed performance; high risk with uncertain momentum. |
| 2026-07-01 | Hold | Buy | Strong recent performance and positive momentum indicators. |
| 2026-06-25 | Sell | Hold | Positive momentum, but recent volatility raises concerns. |
| 2026-06-09 | Hold | Sell | Weak momentum and high risk; cautious outlook advised. |
| 2026-05-29 | Sell | Hold | Strong recent performance, but long-term momentum is negative. |
| 2026-05-10 | Hold | Sell | Weak momentum and high risk overshadow potential upside. |
| 2026-05-08 | — | Hold | Strong recent performance and positive earnings surprise. |
| 2026-05-07 | Sell | Hold | Компания показывает положительную динамику выручки, но значительное снижение цены акций за последние месяцы указывает на высокие риски. Рекомендуется удерживать акции до ясности в трендах. |
| 2026-04-25 | Hold | Sell | Компания демонстрирует значительное снижение цены акций за последние месяцы, что указывает на высокие риски. Несмотря на положительные показатели выручки, общий тренд негативный. |
| 2026-02-26 | Sell | Hold | Компания показала сильный рост за последний месяц, но имеет значительное снижение за более длительный период. Рекомендуется удерживать акции до прояснения ситуации на рынке. |
| 2026-01-27 | Hold | Sell | Компания демонстрирует значительное снижение цен на акции за последние 60 и 120 дней, что указывает на нестабильность. Отсутствие данных по EPS и дивидендам также создает дополнительные риски для инвесторов. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-10-20 | Piper Sandler | Target Lowered | 732 → 561 | 383.09 |
| 2026-10-15 | Raymond James | Target Lowered | 800 → 675 | 402.8704 |
| 2026-09-03 | Argus Research | Target Raised | 460 → 600 | 506.98 |
| 2026-08-06 | Morgan Stanley | Target Raised | 600 → 640 | 528.41 |
| 2026-08-06 | Goldman Sachs | Target Raised | 535 → 715 | 561.47 |
| 2026-08-06 | Piper Sandler | Target Raised | 724 → 732 | 551.4 |
| 2026-08-06 | Barclays | Target Raised | 523 → 688 | 609.49 |
| 2026-07-13 | Piper Sandler | Target Raised | 674 → 724 | 565.8 |
| 2026-07-06 | Needham | Target Raised | — → 750 | 597.04 |
| 2026-06-15 | Piper Sandler | Update | — → 674 | 457.32501 |
| 2026-05-08 | Barclays | Target Lowered | 682 → 523 | 426.89 |
| 2026-05-07 | Morgan Stanley | Target Lowered | 675 → 600 | 433.82 |
| 2026-05-07 | Goldman Sachs | Target Lowered | 625 → 535 | 434.5 |
| 2026-05-07 | UBS | Target Lowered | 570 → 440 | 416.57 |
| 2026-04-08 | Morgan Stanley | Update | — → 675 | 391.53 |
| 2026-04-08 | Goldman Sachs | Target Lowered | 720 → 625 | 391.53 |
| 2026-02-25 | Robert W. Baird | Target Lowered | 900 → 800 | 523.63 |
| 2026-02-25 | Craig-Hallum | Target Lowered | — → 820 | 543.4708 |
| 2026-02-25 | RBC Capital | Target Lowered | — → 735 | 543.24 |
| 2026-02-25 | Piper Sandler | Target Lowered | — → 690 | 548.225 |
| 2026-01-06 | Northcoast Research | Rating Upgraded | — → 742 | 591.16 |
| 2025-12-17 | Morgan Stanley | Target Lowered | 760 → 713 | 555.06 |
| 2025-11-17 | RBC Capital | Update | — → 860 | 554.37 |
| 2025-11-05 | Piper Sandler | Target Lowered | — → 753 | 622.38 |
